IFNA2 and neoplasm: Of note, unmodified or pegylated variants of human recombinant IFN-α2a or IFN-α2b have been approved by the US Food and Drug Administration (FDA) and other regulatory agencies worldwide for use in patients with various neoplasms, including chronic myelogenous leukemia (CML) [33].